middle east and africa peptide therapeutics Market

The Middle East and Africa peptide therapeutics market is expected to reach US$ 1,940.12 million by 2027 from US$ 1,178.53 million in 2019; it is estimated to grow at a CAGR of 6.5% from 2020 to 2027. The growth of the Middle East and Africa peptide therapeutics market is attributed to key driving factors, such as growing investments in peptide therapeutics and increasing prevalence of metabolic disorders and infectious diseases. However, operational limitations of peptides are expected to restrain the growth of the market during the forecast period.

Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. Continuous R & D activities in peptide therapeutics have discovered its benefits in tackling a range of chronic disorders, such as renal disorders, genetic conditions, oncology, and neurodegenerative conditions. Over 7,000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions as neurotransmitters, hormones, ion channel ligands, and growth factors. The effectiveness of the outcomes of peptide therapies is generating investments in the development of new drugs. Also, increasing prevalence of metabolic and infectious diseases is one of the prominent factors expected to drive the peptide therapeutics market. International Diabetes Federation (IDF) revealed that, in 2017, 17.3% of population of the UAE between the ages of 20 and 79 was suffering from type 2 diabetes. Hence, increase in investments in the development of new drugs for peptide therapies and applicability of therapies for treatment of viral infections and chronic diseases are expected to accelerate the growth of the peptide therapeutics market during the forecast period.

The outbreak of the COVID-19 pandemic has extensively affected the countries in the Middle East and Africa region. The COVID-19 outbreak has caused massive disruptions in supply chains and affected these countries' research and development activities in 2020. As the Middle East countries are highly dependent on medical devices and pharmaceutical products imported from developed countries, these factors would likely to negatively affect the market.

Based on type, the Middle East and Africa peptide therapeutics market is segmented into generic and innovative. The innovative segment held the largest share of the market in 2019, whereas the generic segment is anticipated to register the highest CAGR in the market during the forecast period.

In terms of route of administration, the Middle East and Africa peptide therapeutics market is categorized into parenteral, oral, mucosal, pulmonary, and others. The parenteral segment held the largest share of the market in 2019; however, the oral segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on synthesis technology, the Middle East and Africa peptide therapeutics market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. The solid phase peptide synthesis segment held the largest share of the market in 2019. The hybrid technology segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on application, the Middle East and Africa peptide therapeutics market is categorized into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest share of the market in 2019. However, the metabolic disorder segment is estimated to register the highest CAGR in the market during the forecast period.

Primary and secondary sources associated with this report on the Middle East and Africa peptide therapeutics market include International Diabetes Federation (IDF), International Agency for Research on Cancer, (IARC) and World Health Organization (WHO).